Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Chu

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
Cancer Chemotherapy and Pharmacology|August 4, 2017
Phase I study of veliparib in combination with gemcitabineRonald Stoller, John C Schmitz, Fei Ding, et al.
Journal of the National Cancer Institute. Monographs|November 16, 2017
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion ReportDan Xi, Ting Bao, Qi Chen, et al.
Breast Cancer Research and Treatment|February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
Elife|March 28, 2023
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trialAstha Thakkar, Kith Pradhan, Benjamin Duva, et al.
Cancer Chemotherapy and Pharmacology|September 25, 2019
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignanciesLeonard J Appleman, Jan H Beumer, Yixing Jiang, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Circulation. Arrhythmia and Electrophysiology|October 7, 2020
Malignant Arrhythmias in Patients With COVID-19: Incidence, Mechanisms, and OutcomesMohit K Turagam, Daniel Musikantow, Martin E Goldman, et al.
JACC. Clinical Electrophysiology|April 25, 2021
Atrial Fibrillation in Patients Hospitalized With COVID-19: Incidence, Predictors, Outcomes, and Comparison to InfluenzaDaniel R Musikantow, Mohit K Turagam, Samantha Sartori, et al.
Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Cancer Chemotherapy and Pharmacology|August 4, 2017
Phase I study of veliparib in combination with gemcitabineRonald Stoller, John C Schmitz, Fei Ding, et al.
Journal of the National Cancer Institute. Monographs|November 16, 2017
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion ReportDan Xi, Ting Bao, Qi Chen, et al.
Breast Cancer Research and Treatment|February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
Elife|March 28, 2023
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trialAstha Thakkar, Kith Pradhan, Benjamin Duva, et al.
Cancer Chemotherapy and Pharmacology|September 25, 2019
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignanciesLeonard J Appleman, Jan H Beumer, Yixing Jiang, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Circulation. Arrhythmia and Electrophysiology|October 7, 2020
Malignant Arrhythmias in Patients With COVID-19: Incidence, Mechanisms, and OutcomesMohit K Turagam, Daniel Musikantow, Martin E Goldman, et al.
JACC. Clinical Electrophysiology|April 25, 2021
Atrial Fibrillation in Patients Hospitalized With COVID-19: Incidence, Predictors, Outcomes, and Comparison to InfluenzaDaniel R Musikantow, Mohit K Turagam, Samantha Sartori, et al.
Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Pageof 22